Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Choi, Jaebok ^a   Cooper, Matthew L ^a   Alahmari, Bader ^a   Ritchey, Julie ^a   Collins, Lynne ^a   Holt, Matthew ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CHEMOKINE RECEPTOR CXCR3; FEDRATINIB; GAMMA INTERFERON RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB; INTERFERON RECEPTOR; JAK1 PROTEIN, MOUSE; JAK2 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONAMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IN VIVO STUDY; LYMPHATIC LEUKEMIA; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OVERALL SURVIVAL; SURVIVAL RATE; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KNOCKOUT MOUSE; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, LEUKEMIC; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; PYRROLIDINES; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; SULFONAMIDES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84907829534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109799     Document Type: Article

References (29)

1. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, et al. (2010) NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant 16:565-586.
2. Paczesny S, Hanauer D, Sun Y, Reddy P (2010) New perspectives on the biology of acute GVHD. Bone Marrow Transplant 45:1-11.
3. Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, et al. (2012) IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 120:4093-4103.
4. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, et al. (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115:5232-5240.
5. Wilson LJ (2010) Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 20:609-623.
6. Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, et al. (2004) Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol 173:3620-3630.
7. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, et al. (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116:129-139.
8. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, et al. (2003) Highpenetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102:1857-1865.
9. Gross S, Piwnica-Worms D (2005) Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2:607-614.
10. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Jr., et al. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88:3230-3239.
11. van den Elsen PJ, Gobin SJ, van Eggermond MC, Peijnenburg A (1998) Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 48:208-221.
12. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189.
13. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, et al. (2014) Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood.
14. Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, et al. (2013) Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 4:15-35.
15. Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, et al. (2013) AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18:819-820.
16. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311-320.
17. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109-3117.
18. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497.
19. Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281-1283.
20. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M (1998) Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 91:3315-3322.
21. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE, 3rd (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140:13-21.
22. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, et al. (2010) Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116:5738-5747.
23. Vogtenhuber C, Bucher C, Highfill SL, Koch LK, Goren E, et al. (2010) Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood 116:466-474.
24. Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, et al. (2011) The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 1:e46.
25. Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, et al. (2014) Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 20:2674-2683.
26. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, et al. (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272-1277.
27. Yi T, Chen Y, Wang L, Du G, Huang D, et al. (2009) Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114:3101-3112.
28. Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, et al. (2011) Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest 121:1445-1455.
29. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F (2013) The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res 19:327-335.